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SUMMARY
Introduction: Cardiovascular events occur 50 times more often in kidney transplant patients 
than in the general population and are the leading cause of death. The aim of the study was 
to evaluate the behavior of cardio-metabolic profile and determine the incidence of major 
cardiovascular events in the first year after transplantation.
Methods: This prospective study evaluated the behavior of cardio-metabolic profile in adult 
patients that were transplanted during 2011.
Results: The median age was 44.3 ± 12.05 years, 68.7 % were men and 95.5 %, hypertensive. 
Alemtuzumab-cyclosporine and steroids were used in 89.6 %, delaying the introduction of the 
antimetabolite. In the first year after transplantation there were three cases of diabetes melli-
tus, three major cardiovascular events, and 12 cases of acute rejection. Albumin, hemoglobin, 
weight, body mass index (BMI), calcium and HbA1C increased (p<0.05), whereas paratohormone, 
phosphorus, creatinine and uric acid decreased (p<0.05). Glomerular filtration rate (GFR) was 
higher in patients without rejection (p=0.001).
Conclusion: This immunosuppressive protocol with alemtuzumab, cyclosporine and steroids, 
and the delayed introduction of the antimetabolite improved bone mineral metabolism, uric 
acid, albumin and hemoglobin, but there were negative effects on HbA1c, weight and BMI. 
There was a low incidence of new onset diabetes mellitus and major cardiovascular events.
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RESUMEN
Seguimiento por un año de la evolución del perfil 
cardiometabólico en pacientes trasplantados rena-
les tratados con alemtuzumab, ciclosporina y este-
roides en un hospital de referencia en Colombia
Introducción: en los pacientes trasplantados renales 
los eventos cardiovasculares ocurren 50 veces más 
que en la población general y son la principal causa de 
muerte. El objetivo del estudio fue evaluar el compor-
tamiento del perfil cardio-metabólico y determinar la 
frecuencia de eventos cardiovasculares mayores en el 
primer año del trasplante.
Métodos: estudio prospectivo en el que se evaluó el 
perfil cardio-metabólico en 67 pacientes adultos tras-
plantados durante el 2011.
Resultados: la edad promedio fue 44,3±12,05 años, 
68,7 % eran hombres y 95,5 %, hipertensos. En el 89,6 % 
se empleó alemtuzumab-esteroides y ciclosporina e in-
troducción tardía del antimetabolito. Se presentaron 3 
diabetes mellitus postrasplante, 3 eventos cardiovascu-
lares mayores y 12 rechazos agudos. Al año, la albúmi-
na, la hemoglobina, el índice de masa corporal, el cal-
cio y la HbA1C aumentaron con respecto al valor previo 
al trasplante (p<0,05), mientras que la paratohormona, 
el fósforo, la creatinina y el ácido úrico disminuyeron 
(p<0,05). La  tasa de filtración glomerular (TFG) al año 
fue mayor en los pacientes sin rechazo (p 0,001).
Conclusión: la terapia inmunosupresora con alemtu-
zumab–ciclosporina-esteroides mostró que al año del 
trasplante hubo mejoría significativa del metabolismo 
mineral óseo, el ácido úrico, la albúmina y la hemoglo-
bina, pero empeoraron significativamente la HbA1c, el 
peso y el IMC, con una baja frecuencia de casos nuevos 
de diabetes mellitus y eventos cardiovasculares mayores.
PALABRAS CLAVE
Enfermedad Cardiovascular; Factores de Riesgo Car-
diovascular; Trasplante Renal
RESUMO
Seguimento por um ano da evolução do perfil car-
diometabólico em pacientes transplantados renais 
tratados com alemtuzumabe, ciclosporina e esteroi-
des num hospital de referência na Colômbia
Introdução: Nos pacientes transplantados renais os 
eventos cardiovasculares ocorrem 50 vezes mais do 
que na população geral e são a principal causa de 
morte. O objetivo do estudo foi avaliar o compor-
tamento do perfil cardio-metabólico e determinar a 
frequência de eventos cardiovasculares maiores no 
primeiro ano do transplante.
Métodos: Estudo prospectivo onde se avaliou o perfil 
cardio-metabólico em 67 pacientes adultos transplan-
tados durante o 2011. 
Resultados: A idade média foi 44,3±12,05 anos, 68,7 % 
homens e 95,5 % hipertensos. Em 89,6 % se empregou 
alemtuzumabe-esteroides e ciclosporina e introdução 
tardia do antimetabólito. Apresentaram-se 3 diabete 
mellitus pós-transplante, 3 eventos cardiovasculares 
maiores e 12 rejeições agudas. Ao ano, a albumina, 
hemoglobina, índice de massa corporal, cálcio e a 
HbA1C aumentaram com respeito ao valor prévio ao 
transplante (p<0,05), enquanto o paratormônio, fós-
foro, creatinina e ácido úrico diminuíram (p<0,05). 
A TFG ao ano foi maior nos pacientes sem rejeição 
(p 0,001).
Conclusão: A terapia imunossupressora com alem-
tuzumabe–ciclosporina-esteroides mostrou que ao 
ano do transplante há melhoria significativa do me-
tabolismo mineral ósseo, ácido úrico, albumina e he-
moglobina mas piorou significativamente a HbA1c, 
o peso e o IMC, com uma baixa frequência de casos 
novos de diabetes mellitus e eventos cardiovasculares 
maiores.
PALAVRAS CHAVES
Doença Cardiovascular; Fatores de Risco Cardiovas-
culares; Transplante Renal
INTRODUCTION
The main causes of death in renal transplant patients 
are cardiovascular events, followed by infection and 
neoplasms. Non-fatal cardiovascular events occur 
annually in 3.5 % to 5 % of renal transplant patients, 
which is 50 times higher than in the general popula-
tion (1,2). Traditional risk factors are involved; how-
ever, these patients are exposed to steroids and im-
munosuppressive drugs that favor weight gain, insulin 
resistance, diabetes onset, or decompensation, and 
these drugs may even promote changes in lipid pro-
files, thus worsening baseline hypertension control (3). 
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However, the development of these risk factors varies 
among patients, possibly due to differences between 
baseline characteristics and the type of immunosup-
pressive drug used. 
Metabolic changes primarily occur in the first year, but 
cardiovascular events typically occur later. The aim of 
this study was to evaluate the evolution of the cardio-
metabolic profile and determine the frequency of ma-
jor cardiovascular events 1 year after transplantation.
METHODOLOGY
This study assessed the cardio-metabolic profile of 
patients with end-stage chronic kidney disease (CKD) 
before and after transplantation between January 1 
and December 31, 2011 at a high-complexity hospital 
in Medellin, Colombia.
All renal transplant patients over 18 years of age dur-
ing the afore-mentioned period were included in 
the study. Electronic medical records of all identified 
cases were reviewed, and the following variables were 
also accounted for: demographic characteristics (age, 
sex, and race); etiology of CKD and the personal his-
tory of the recipient; donor characteristics (age, sex, 
and cause of death); cytomegalovirus (CMV) serosta-
tus and donor-recipient HLA compatibility; transplant 
characteristics (cold ischemia time, warm ischemia 
time, monoclonal induction therapy, and immuno-
suppression protocol); and the presence of cardiovas-
cular events, death, acute rejection, graft loss, recent 
onset diabetes mellitus after transplantation (NODAT) 
and CMV infection in the first year. 
The following pre-transplant variables were deter-
mined at 3, 6 and 12 months after the procedure: cre-
atinine (mg/dL), hemoglobin (g/dL), albumin (g/dL), 
calcium (mg/dL), parathyroid hormone (PTH, pg/dL), 
phosphorus (mg/dL), total cholesterol (mg/dL), HDL 
cholesterol (mg/dL), LDL cholesterol (mg/dL), triglyc-
eride (mg/dL), fasting glucose (mg/dL), and glycosyl-
ated hemoglobin (HbA1c, %) levels; glomerular filtra-
tion rate (GFR, mL/min), weight (kg), and body mass 
index (BMI, kg/m2). The GFR was calculated using the 
Modification of Diet in Renal Disease Study (MDRD) 
equation (4). The following staging of post-transplant 
CKD was defined: stage 1, creatinine clearance >90 mL/
min; stage 2, between 60 and 89 mL/min; stage 3a, 
between 45 and 59 mL/min; stage 3b, between 30 and 
44 mL/min; stage 4, between 15 and 29 mL/min; and 
stage 5, <15 mL/min.
The data were recorded in an MS-Excel® database de-
signed for the study, and analyzed with SPSS® version 
18.0 (SPSS Inc., Chicago, Illinois, USA). 
The categorical variables were expressed as absolute 
and relative values. For continuous quantitative vari-
ables, normality assumptions were verified with the 
Kolmogorov-Smirnov test. Continuous quantitative 
variables with normal distributions were expressed 
as means ( x ̅     ) and standard deviation (SD). Discrete 
variables or those that did not fulfill the normality as-
sumption were expressed as medians (Me) and inter-
quartile ranges (IQR). 
Inferential statistics were performed to compare vari-
ables before and after transplantation. Variable com-
parisons were also conducted one year after trans-
plantation based on the presence of rejection and 
CKD staging after transplantation. McNemar’s test for 
paired data was performed for qualitative variables of 
related samples. For the quantitative variables, Stu-
dent’s t-test for related samples was done if the dif-
ference fulfilled the assumption of normality, and a 
Wilcoxon test was performed when the assumption 
was not fulfilled. For independent samples, Student’s 
t-test was used to compare quantitative variables. A 
Kruskal-Wallis test was performed for comparisons ac-
cording to the CKD stages. An alpha of 0.05 was used 
for all inferential statistical tests. No replacements 
were done for missing data.
This study was approved by the Research and Ethics 
Committee of the Pablo Tobon Uribe Hospital.
RESULTS
In 2011, 67 kidney transplants were performed, and 
68.7 % of the patients were male. The mean age 
was 44.3 years (SD ± 12.05). Three patients were 
black. The average BMI was 24.5 kg/m2 (SD: 4.07). 
The main causes of CKD were primary glomeru-
lopathies in 25.4 % followed by unknown etiologies 
in 17.9 %. In total, 74.6 % of the patients received 
renal replacement therapy before transplantation, 
and 54 % had  hemodialysis, which was the most 
common type of dialysis therapy. The median time 
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Table 1. Baseline characteristics of transplant patients
Variables n = 67
Demographic characteristics of the recipients
Black race n (%) 3 (4.5)
Body mass index n (%)
<20 11 (16.4)
20-25 29 (43.3)
25-30 20 (29.9)
>30 7 (10.4)
Etiology of chronic kidney disease of the recipient n (%)
Primary glomerulopathy 17 (25.4)
Unknown 12 (17.9)
Diabetes mellitus 11 (16.4)
Arterial hypertension 8 (11.9)
Unclassified glomerulopathy 5 (7.5)
Polycystic kidney disease 5 (7.5)
Tubulointerstitial nephritis 4 (6.0)
Hereditary familial nephritis 2 (3.0)
Obstructive uropathy 2 (3.0)
Lupus nephritis 1 (1.5)
Medical history of the recipient n (%)
Arterial hypertension 64 (95.5)
Diabetes mellitus 16 (23.9)
Dyslipidemia 11 (16.4)
Heart failure 4 (6.0)
Coronary heart disease 1 (1.5)
Smoking
Never 56 (83.6)
Occasionally 11 (16.4)
Renal replacement therapy 50 (74.6)
Hemodialysis 27 (54)
Peritoneal dialysis 23 (46)
Hepatitis C infection 1 (1.5)
Previous transplant 1 (1.5)
Cytomegalovirus serostatus n (%)
D+/R+ 50 (74.6)
D-/R+ 11 (16.4)
D+/R- 3 (4.5)
D-/R- 3 (4.5)
on dialysis therapy was 21 months (range: 1 month 
to 7 years). Regarding medical histories, arterial hy-
pertension was present in 95.5 % of patients, and 
diabetes mellitus (DM) occurred in 23.9 %. One pa-
tient suffered from pre-transplant coronary artery 
disease, no patients were active smokers, and one 
patient had previously received a transplant. The 
donor-recipient compatibility, CMV serostatus, and 
other characteristics of the recipients are shown in 
table 1.
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All transplants were performed from standard criteria 
deceased donors. In total, 74.6 % of donors were male 
with a mean age of 29.1 ± 11.7 years. The main etiol-
ogy of donor brain death was craniocerebral trauma, 
which occurred in 85.1 % of the cases. The cold and 
warm ischemia times are shown in table 1. 
Monoclonal antibodies were used as induction thera-
py in 98.5 % of the patients: six patients were treated 
with basiliximab, and the remaining 60 received alem-
tuzumab. This type of induction therapy was not used 
in a 60-year-old woman with a history of hepatitis C 
infection, in whom induction was performed with 
only methylprednisolone. In the immunosuppression 
regimen, cyclosporine was used in 80.6 % of patients 
as the initial calcineurin inhibitor drug, The combi-
nation regimens with antimetabolites are described in 
table 1. 
Behavior of the metabolic profile variables of patients 
pre-transplant and at 3, 6, and 12 months post-trans-
plant is shown in figure 1. The GFR was 67.98 mL/min 
(SD ± 19.09) 1 year after transplantation. After classi-
fying the average GFR according to the stages of CKD 
(n=64 patients), 9 (14 %) patients were in stage 1, 34 
(53,1 %) in stage 2, 13 (20.3 %) in stage 3a, 5 (7,8 %) in 
stage 3b, 2 (3,1 %) in stage 4 and 1 patient (1,6 %) in 
stage 5.
Variables n = 67
HLA A, B, DR incompatibility n (%)
2/6 1 (1.5)
3/6 6 (9.0)
4/6 17 (25.4)
5/6 32 (47.8)
6/6 11 (16.4)
Donor characteristics
Deceased donor n (%) 67 (100)
Male n (%) 50 (74.6)
Age, x ̅      (SD) 29.1 (11.7)
Donor death cause n (%)
Craniocerebral trauma 57 (85.1)
Cerebrovascular accident 7 (10.4)
Cerebral anoxia 3 (4.5)
Transplant information
Cold ischemia (hours) Me (p25-p75) 12.5 (10-19)
Warm ischemia (minutes) Me (p25-p75) 30 (30-45)
Monoclonal induction therapy n (%) 66 (98.5)
Basiliximab 6 (9.0)
Alemtuzumab 60 (89.6)
Initial immunosuppression regimen n (%)
Cyclosporine + Mycophenolate + Prednisolone 33 (49.3)
Cyclosporine + Azathioprine + Prednisolone 21(31.3)
Tacrolimus + Mycophenolate + Prednisolone 4 (6)
Tacrolimus + Azathioprine + Prednisolone 3 (4.5)
Cyclosporine + Prednisolone 6 (9)
Table 1. Baseline characteristics of transplant patients (continued)
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Events 1 year after transplantation
Twelve patients exhibited acute graft rejection, as 
confirmed by a renal biopsy. The histological report 
showed cellular rejection in five patients, humoral 
rejection in four, and mixed rejection in the remain-
ing three. None of these patients had graft loss. Six 
patients required a change in immunosuppressive 
therapy to rapamycin pathway inhibitors: four pa-
tients due to calcineurin inhibitor toxicity, one patient 
due to concomitant severe infection, and the re-
maining one due to low-grade epithelial neoplasia. 
In one patient, a BK virus infection was document-
ed. Only one patient lost the kidney graft, and this 
loss was secondary to the deliberate suspension of 
immunosuppression due to a life-threatening infec-
tion. Two patients died, one 11 days and the other 61 
days after transplantation. Both of them died with 
a functional graft, and the cause of death in both 
Figura 1. Metabolic profile variables prior to transplantation and at 3, 6 and 12 months post-transplant 
IATREIA Vol 28(4) octubre-diciembre 2015
394
was cardiovascular. One patient suffered an acute 
myocardial infarction that required endovascular 
therapy but did not cause death. Twelve patients 
suffered from CMV infections; the median time of 
infection was 52 days after transplantation (p25 
and p75, 42 and 105 days, respectively). Survival of 
patients 61 days after kidney transplantiation was 
97 % (figure 2).
Figura 2. The Kaplan-Meier curve for graft survival of renal transplant patients at the 
12-month follow-up (365 days)
Of the 51 patients who had no history of diabetes mel-
litus, three (5.8 %) developed this disease after trans-
plantation: two of them were diagnosed with DM in 
the initial 3 months, and the other, at 6 months. All 
patients who experienced acute rejection received cy-
closporine as an initial immunosuppression therapy, 
which was later changed to tacrolimus. No patient on 
the immunosuppressive therapy with tacrolimus had 
an initial rejection.
At 1 year, levels of albumin, hemoglobin, BMI, weight, 
calcium, and HbA1c were increased from the base-
line values prior to the transplant and were statisti-
cally significant, whereas those of PTH, phosphorus, 
creatinine, and uric acid were decreased during this 
period (table 2). The remaining variables considered 
in this study, such as the LDL cholesterol, total choles-
terol, triglycerides, use of antihypertensive drugs and 
blood glucose, were not significantly different. Renal 
function 1 year after transplantation was significantly 
different in patients who had rejection compared to 
those who did not have it (mean DS 51.27 ± 12.05 vs. 
71.74 ± 18.42; p = 0.001). When patients were com-
pared according to post-transplant CKD stages, levels 
of the different metabolic profile variables were not 
significantly different between the CKD stages, except 
for triglycerides.
DISCUSSION
The study showed that renal transplant patients had 
significantly improved cardio-metabolic profiles at 
the 1-year follow-up with respect to renal function, 
bone mineral metabolism, nutritional status, and 
anemia. However, a significant increase in the BMI 
and impaired carbohydrate metabolism were found, 
along with a low frequency of NODAT occurrence and 
a non-negligible frequency of major cardiovascular 
events. 
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To our knowledge, few studies on this subject have 
been performed in Latin America. Perez A et al., re-
ported a cardiovascular disease prevalence of 73 % 
in a cohort of 63 Cuban kidney transplant patients 
followed for 1 year; however, the study does not de-
scribe how long ago these patients were transplanted, 
which limits the interpretation of these data because 
the length of time from transplantation is directly pro-
portional to the cardiovascular risk (5). In our study, 
4.47 % (3/67) of the patients presented cardiovascular 
events during the first post-transplant year, which 
were significant. Rodelo J et al., in a Colombian series 
of 201 elderly kidney transplanted patients followed 
for 7 years, found that the main causes of death (38 
%) were of cardiovascular origin; however, this was 
an older population with a longer follow up period, 
which may explain the high mortality rate (6). Roberts 
et al. reported an incidence of main cardiovascular 
events of 8.2 % (five patients with acute myocardial 
infarction and one with cerebrovascular disease) in a 
registry of the only center in Trinidad and Tobago of 
kidney transplanted patients (with living donors) who 
were followed for 5 years, but the majority of these 
events occurred during the first year after transplantation 
(three patients with acute myocardial infarction and 
one with cerebrovascular disease). In this paper, the 
weight gain, NODAT, and dyslipidemia in the first year 
after transplant were 21.9 %, 9.6 %, and 23 %, respec-
tively (7).
The 1 year survival of patients was 97 %, which was 
similar to the results described in studies using alemtu-
zumab as induction therapy or in those using different 
inductors (8-14). The cause of death in two patients was 
cardiovascular, and both died with a functional graft. 
Both patients were diabetic, and no preventable car-
diovascular cause was identified in their pre-transplant 
protocol. Only one patient suffered a non-fatal acute 
myocardial infarction, which was treated and did not 
affect graft function. Major cardiovascular events oc-
curred in 4.5 % (3/67) of the patients and caused deaths 
in 2 patients (2.98 %). The annual risk of cardiovascular 
death in renal transplant patients ranged from 3.5 % 
to 5 %, which is 50 times higher than in the general 
population (1,15). This range was estimated to include 
a non-negligible rate of cardiovascular events due to 
the short follow-up time, which showed the high car-
diovascular risk of these patients due to their underlying 
CKD and multiple comorbidities.
Table 2. Metabolic profile of transplant patients before and 1 year after transplantation 
Variable Pre-transplant (x–   ±SD) Post-transplant (x–   ±SD) Difference (x–   ±SD) p
Albumin (g/dL) 4.0±0.5 4.2±0.3 0.2±0.5 0.002a
Hemoglobin (g/dL) 11.9±1.7 14.1±1.2 2.2±2.7 0.000a
BMI (kg/m2) 24.5±4 26±4 1.5±2.9 0.000b
Weight (kg) 69.1±14 73.6±13.5 4.5±6.9 0.000a
Creatinine (mg/dL) 8±4 1.2±0.4 -6.8±4.1 0.000a
Parathyroid hormone (pg/mL) 251.7±233 83±36.8 -198.1±248.7 0.000b
Calcium (mg/dL) 8.9±1.3 9.4±1.1 0.5±1.92 0.000b
Phosphorus (mg/dL) 4.3±1.4 3.5±0.6 -1.2±1.6 0.000a
LDL cholesterol (mg/dL) 103±34.1 112.6±41 8.9±47.7 0.182a
HDL cholesterol (mg/dL) 41.9±12.7 47.8±12.7 7.5±13.6 0.000a
Use of statins n (%) 18 (26.9) 37 (55.2) 0.001c
HbA1c (%) 5.4±1.8 6±1.40 0.8±1.3 0.000b
Abbreviations: BMI, body mass index; LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1c, glycosylated hemoglobin
aStudent’s t test for related samples. bWilcoxon test. cMcNemar’s test 
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Censored graft survival was 98.5 %, which was higher 
than that reported in other series (8-10,14). Only one 
patient lost the graft as a result of the deliberate suspen-
sion of immunosuppression due to a life-threatening 
infection. The frequency of biopsy-proven rejec-
tion in this study with a regimen of alemtuzumab, 
cyclosporine, steroids, and the delayed introduction 
of antimetabolites was 17 %. All patients received 
the appropriate treatment according to the rejection 
type, and no graft losses had occurred from rejection 
at the one-year follow-up. Other studies of similar 
immunosuppression regimens report rejection rates 
between 10.4 % and 24 % (14,16,17). These results are 
similar to those described in the literature using other 
induction and maintenance regimens (8-13,18). This 
study also showed that transplant rejection signifi-
cantly affected graft function (51.27 ± 12.05 vs. 71.74 
± 18.42). Several studies have reported that a lower 
GFR at the 1 year follow-up is a negative factor for 
long-term graft survival (19-21). It is important to ac-
count for the rejection rate because steroid mega-
doses and increased immunosuppression are used to 
treat rejection and could influence subsequent car-
diovascular events. However, we observed no signifi-
cant differences in this respect at the 1 year follow-up 
of our patients. 
Most patients had good graft function 1 year after 
transplantation, as shown by an average GFR of 
67.9 ± 19 mL/min, and 61 % of patients remained 
in stages 1 and 2 of CKD. For the different series and 
induction regimens available, GFR values at the 12 
month follow-up have ranged from 53 to 68 mL/min 
(9-11,13). These results, coupled with the available 
evidence, demonstrate how transplantation is the 
best therapy for patients with CKD, not only because 
the disease reverts to an earlier stage but also because 
this treatment increases survival and improves quality 
of life compared to patients treated by dialysis (22-24). 
In the (ELITE)-Symphony study, the GFR calculated 
by the MDRD equation in four groups was lower than 
that in this study, which may be most likely explained 
by the younger age of our donors, and because none 
were extended-criteria donors (13).
Most patients quickly experienced a recovery of 
the biochemical properties used to assess the bone 
mineral profile, which was demonstrated by signifi-
cant improvements in the serum PTH, calcium, and 
phosphorus levels within the initial 3 months, which 
were maintained throughout the 1-year follow-up. 
Similarly, hemoglobin levels significantly improved 
without the use of erythropoiesis-stimulating agents. 
Although the immunosuppression regimen was based 
on calcineurin inhibitors, uric acid significantly de-
creased without the use of hypouricemic drugs. 
Similar results have been previously published, and 
this outcome is correlated with the recovery of renal 
function (25-29). In patients with end-stage CKD, most 
cardiovascular mortality is associated with bone min-
eral metabolism and blood disorders, which occur up 
to 7.9 times more frequently than in the general popu-
lation and at twice the rate observed in transplant pa-
tients. Renal transplantation is the best alternative to 
improve survival in these patients (22-24,30-33).
Only 5.9 % of the patients in our series developed 
NODAT based on the standard criteria of the Ameri-
can Diabetes Association, which was similar to the 
result observed in the cyclosporine group of the 
(ELITE)-Symphony study and lower than the diabetes 
rate reported when tacrolimus was used for treatment 
(13,34-37). However, it should be noted that 39.2 % of 
the patients were classified at the 1 year follow-up 
as pre-diabetic according to the current guidelines. 
Nonetheless, we cannot interpret the significant in-
creases observed in the HbA1c levels compared to 
those before transplantation due to limitations of 
the interpretation of HbA1c levels in patients with 
CKD that undergo dialysis (38-40). We believe that the 
above results could be explained by the drugs used 
and the increased BMI of patients at the 1 year follow-
up (p < 0.001). Prior to transplantation, 38.8 % of the 
patients had a BMI>25. After transplantation, the 
percentage increased to 52.23 %, which classified the 
patients as overweight and obese which, according 
to the literature, is a determining factor for insulin 
resistance and impaired carbohydrate metabolism 
and can influence long-term cardiovascular morbid-
ity and mortality (35,41-44).
Significant increases in cholesterol and triglycerides 
were observed in the initial 3 months after transplan-
tation, but with progressive improvement in subse-
quent months and levels similar to those observed 
pre-transplant at the 1 year follow-up. The initial 
increase was explained by the effect of immunosup-
pressive drugs on lipoproteins, and the subsequent 
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improvement was explained by the increased use 
of oral lipid-lowering drugs, which, in this study, 
increased from 26.9 % prior to transplantation to 55.2 % 
at the 1 year follow-up. Dyslipidemia is considered a 
known cardiovascular risk factor, and its association 
with cardiovascular disease has been demonstrated in 
several studies with longer follow-ups (1,45-47).
Among the limitations of this study, we should note 
that it was performed in a single clinical center, to 
which patients were referred by their insurers with an 
indication for renal transplantation, resulting in the 
possibility of a selection bias for patients with better 
baseline statuses, better social support, and better 
pre-transplant health insurance coverage. A 1 year 
follow-up of a patient is a short period to correlate 
cardio-metabolic variables with clinically important 
cardiovascular outcomes, coupled with the inability 
to follow-up some patients due to the requirements 
imposed by insurance companies. Blood chemistry 
measurements were performed in different laborato-
ries, thus making it difficult to standardize the results. 
The power to demonstrate differences in subgroups 
according to the stage of CKD was limited by the 
small sample size. The ability to perform clinical and 
paraclinical follow-ups in 90 % of patients was one of 
the strengths of our transplant group and the study. 
In conclusion, patients with CKD have multiple 
cardio-metabolic abnormalities that improve with 
renal transplantation; however, this population con-
tinues to exhibit non-negligible multiple modifiable 
risk factors and major cardiovascular outcomes at 
the 1 year follow-up. The authors recommend the 
follow-up and treatment of these factors, which can 
influence short- and long-term cardiovascular mor-
bidity and mortality.
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